Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
to discontinue cancer drug trial, in: (2008)
Providers adjust based on your progress, side effects, and evolving needs
Final Phase IIa study results evaluating the CXCR4 antagonist BL-8040 in combination with cytarabine (Ara-C) for the treatment of relapsed/refractory AML patients
BMJ open
GHK-cu $24.99 $34.99Price range: $24.99 through $34.99 Ships next business day (MonFri) Research Focus: Tissue remodeling & skin-support pathways Application: Laboratory and experimental use Format: High-purity lyophilized copper peptide For laboratory research use only
References Noom
US$ 27.07
US$ 20.20
US$ 26.41
US$ 23.66
US$ 27.01
